NEW YORK (GenomeWeb) – German molecular diagnostics firm Epigenomics today reported an 83 percent jump in third quarter revenues, which were driven by increased sales of its Epi proColon blood-based colorectal cancer screening test.

For the three-month period ended Sept. 30, Epigenomics revenues rose to €864,000 ($950,000) from €471,000 in the same period last year. Product revenues were up 95 percent year-over-year to €857,000 from €440,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.